Pulmonary Hypertension Association (PHA) staff and medical leadership presented research findings and interacted with global health care professionals with an interest in pulmonary hypertension (PH) at the American Thoracic Society (ATS) International Conference this week in Dallas. Michael Gray, vice president of quality care and research, shared research findings of current trends among physicians
Individuals with chronic thromboembolic pulmonary hypertension (CTEPH, World Health Organization Group 4 PH) who have surgery to remove blood clots from the lungs could have a better five-year survival rate compared to those individuals who do not have surgery, according to the results of a study of 550 people with CTEPH in the U.K.
New data from “INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in PAH” was presented last week during the 39th International Society for Heart and Lung Transplantation Annual Meeting and Scientific Sessions in Orlando, Fla., by principal investigator Nicholas Hill, M.D., from Tufts University School of Medicine
Dear PH Community, In 1994, just three years after the Pulmonary Hypertension Association (PHA) was founded by three patients and a caregiver, PHA held its first International PH Conference. Its goals were simple, but powerful and, in fact, are still key to Conference’s success today – to have patients gain information from experts, help
The Pulmonary Hypertension Association (PHA) just launched its new Clinical Trial Finder that allows individuals to search for research in pulmonary hypertension (PH), so it seems fitting to highlight a paper published in the most recent edition of Advances in Pulmonary Hypertension, “Basic Science and Clinical Trials: Accelerating the Future.” Authors Stephen J. Halliday,
A recent study published in BMC Pediatrics shows that reliable, objective, early criteria for inhaled nitric oxide (iNO) treatment response in newborns with hypoxic respiratory failure (HRF) still needs to be established. An estimated two percent of babies born in the U.S. are thought to need help breathing using machines. About 35,000 of these
The Pulmonary Hypertension Association (PHA) is pleased to announce the launch of its new Clinical Trial Finder, now available in the research section of the PHA website, PHAssociation.org. PHA provides this tool to help participants learn more about ongoing PH research. The tool includes filters to narrow search results to fit an individual’s personal needs.
A team of researchers has increased the accuracy of a tool used to predict survival for individuals with World Health Organization Group 1 PH (pulmonary arterial hypertension or PAH). CHEST Journal, the official publication of the American College of Chest Physicians, has published a study by Raymond L. Benza, M.D., a cardiologist at Allegheny
Updated guidelines for pulmonary arterial hypertension (PAH) were recently completed by a panel of experts from the Pulmonary Hypertension Association, American Thoracic Society and the American Heart Association and published in the CHEST Journal. The panel, which included several PHA members and a patient representative, looked at 300 recent studies to complete the update
Although the World Symposium on Pulmonary Hypertension (WSPH) has led pulmonary hypertension (PH) to be considered in five classifications, or groups, pediatric PH is more nuanced and there is increasing recognition of unique genotypic and phenotypic subsets of the disease. This necessitates individualized and precision approaches to treatments for children with PH that will